Read news on immunotherapies with our app.
Read more in the app
New study paves way for immunotherapies tailored for childhood cancers
Attivare licenses Wyss Institute’s immune-modulating biomaterial technology to advance immunotherapies - EurekAlert
Two new studies show how immunotherapies collaborate to boost T cell responses in melanoma - EurekAlert
Two new studies show how immunotherapies collaborate to boost T cell responses in melanoma
Overcoming the limits of immunotherapies - EurekAlert
Mutation Mix-Up: Why Some Immunotherapies for Cancer Don’t Always Work As Predicted
